J Korean Fract Soc.  2011 Apr;24(2):212-216. 10.12671/jkfs.2011.24.2.212.

Anti-osteoporotic Drugs and Fracture Healing Mechanism

• Yang KH

• KMID: 2183867
• DOI: http://doi.org/10.12671/jkfs.2011.24.2.212

Abstract

No abstract available.

MeSH Terms

Fracture Healing

Figure

• 

  Fig. 1 Molecular mechanism of action of bisphosphonate.

• 

  Fig. 2 Alendronate increases the callus size compared to control (OVX-ovariectomy), EE2 (estrogen) and RLX (raloxifen).

• 

  Fig. 3 Structure of multicellular remodelling units.

• 

  Fig. 4 Bisphophonate rescue regimen in case of delayed bone formation after osteotomy and distraction.

• 

  Fig. 5 Zoledronate enhances bone in-growth in porous implant.

• 

  Fig. 6 Teriparatide (1-34 PTH) injection shortened the healing time of Colles' fracture.

• 

  Fig. 7 PTH enhances bone growth around the screw and increases pull-out strength significantly compared to control.

Reference

1. Alkhiary YM, Gerstenfeld LC, Krall E, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am. 2005. 87:731–741.

2. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. 25:404–414.

3. Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br. 2005. 87:416–420.

4. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002. 17:2237–2246.

5. Kiely P, Ward K, Bellemore C M, Briody J, Cowell CT, Little DG. Bisphosphonate rescue in distraction osteogenesis: a case series. J Pediatr Orthop. 2007. 27:467–471.

6. Lill CA, Hesseln J, Schlegel U, Eckhardt C, Goldhahn J, Schneider E. Biomechanical evaluation of healing in a non-critical defect in a large animal model of osteoporosis. J Orthop Res. 2003. 21:836–842.

7. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997. 350:550–555.

8. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am. 2007. 89:96–101.

9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005. 90:1294–1301.

10. Skripitz R, Aspenberg P. Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br. 2001. 83:437–440.

11. Yang KH, Won JH, Yoon HK, Ryu JH, Choo KS, Kim JS. High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. Yonsei Med J. 2007. 48:653–658.